This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Merck Serono S. a.. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Estelle Hamelin: Innovator in Prostaglandin Modulation
Introduction
Estelle Hamelin is a notable inventor based in Oxon, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments related to preterm labor and other reproductive health issues. Her innovative work has led to the creation of a patent that addresses critical medical challenges.
Latest Patents
Estelle Hamelin holds a patent for "Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor." This invention is focused on thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea, and for stopping labor prior to cesarean delivery. This patent represents a significant advancement in the management of reproductive health.
Career Highlights
Hamelin is currently associated with Merck Serono S.A., a leading global biopharmaceutical company. Her role at Merck Serono has allowed her to work on groundbreaking research and development projects that aim to improve patient outcomes in reproductive health.
Collaborations
Throughout her career, Estelle has collaborated with esteemed colleagues, including Catherine Jorand-Lebrun and Matthias Schwarz. These collaborations have fostered an environment of innovation and have contributed to the success of her projects.
Conclusion
Estelle Hamelin's contributions to the field of pharmaceuticals, particularly through her patent on thiazolidine carboxamide derivatives, highlight her role as a key innovator in reproductive health. Her work continues to pave the way for advancements in medical treatments.